FARA – EPI-A0001 improves neurological outcome endpoint in 28-Day phase 2A double-blind placebo-controlled clinical trial in Friedreich’s ataxia

Click to download.

PDF: FARA – EPI-A0001 improves neurological outcome endpoint in 28-Day phase 2A double-blind placebo-controlled clinical trial in Friedreich’s ataxia